Compares two chemotherapy combinations in older adults with acute myeloid leukemia
Compares venetoclax with azacitidine against daunorubicin, idarubicin and cytarabine in fit older adults.
Plain-language title generated from the registry record
Registry title: Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Key facts
- Where
- Tianjin, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Source: NCT07132684, who can take part
Where in China
- Blood Diseases HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07132684
- Record updated
- 26 October 2026
- Original description
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.Read full original descriptionShow less
A Multicenter, Randomized, Controlled Clinical Trial Comparing VA and D/IA Induction Regimens in Elderly Patients With Acute Myeloid Leukemia Suitable for Intensive Chemotherapy
This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.
Inclusion: Diagnosis of AML according to WHO (2022) or ICC criteria; Age ≥55 and ≤75 years; ECOG performance status score of 0-2; Adequate organ function:; Total bilirubin ≤1.5× upper limit of normal (ULN); AST and ALT ≤2.5× ULN; Serum creatinine <2× ULN; Cardiac enzymes <2× ULN; Left ventricular ejection fraction (LVEF, by echocardiogram) within normal range Signed informed consent by the patient or legal representative.
Exclusion: Relapsed or refractory AML (previously treated with induction chemotherapy, but hydroxyurea is allowed); Concurrent other malignancies requiring treatment; Severe infectious diseases (e.g., untreated tuberculosis, pulmonary aspergillosis); Other conditions deemed unsuitable by the investigator; Active cardiac disease (e.g., uncontrolled angina, recent myocardial infarction, severe arrhythmias, uncontrolled heart failure, LVEF below normal); Acute promyelocytic leukemia with PML-RARA fusion gene; AML with RUNX1-RUNX1T1 or CBFB-MYH11 fusion genes; AML with BCR-ABL fusion gene.